| Phase 11 trial |
|
Phase 1
|
NCT03833180 |
Mar 2019 → Dec 2023 |
B-cell chronic lymphocytic leukemia, Burkitt lymphoma, Richter transformation, T-cell non-Hodgkin lymphoma +6 |
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Completed
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT06395103 |
Aug 2024 → Mar 2029 expected |
B-cell acute lymphoblastic leukemia, Burkitt lymphoma, Ewing sarcoma, diffuse large B-cell lymphoma +1 |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05562830 |
Nov 2022 → Feb 2029 expected |
urothelial carcinoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT06890884 |
Apr 2025 → Dec 2027 expected |
diffuse large B-cell lymphoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05458297 |
Jul 2022 → May 2029 expected |
B-cell chronic lymphocytic leukemia, Richter transformation, follicular lymphoma, mantle cell lymphoma |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05406401 |
Jul 2022 → Apr 2029 expected |
diffuse large B-cell lymphoma |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05144841 |
Jan 2022 → Apr 2026 |
relapsed/refractory diffuse large B-cell lymphoma |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04504916 |
Oct 2020 → Jun 2023 |
estrogen-receptor positive breast cancer, gastric cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma +2 |
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Terminated
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT05139017 |
Jan 2022 → Sep 2027 expected |
diffuse large B-cell lymphoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06717347 |
Jan 2025 → Jul 2029 expected |
diffuse large B-cell lymphoma |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|